However, immunostaining with anti-ENO1 antibody did not show significant increase of ENO1 levels in the primary HNSCC tissues examined compared with normal tissue samples (data not shown), supporting ENO2 as a more favorable target than ENO1. Here, ENO1 is linked to head and neck squamous cell carcinoma.